key: cord-0699964-wjudxhdy authors: Gul, Muhammad Hamdan; Htun, Zin Mar; Shaukat, Nauman; Imran, Muhammad; Khan, Ahmad title: Potential specific therapies in COVID-19 date: 2020-05-21 journal: Ther Adv Respir Dis DOI: 10.1177/1753466620926853 sha: ade0f0781bc2f198666870b3f620a79d763e854a doc_id: 699964 cord_uid: wjudxhdy COVID-19 has grown into a global pandemic that has strained healthcare throughout the world. There is a sense of urgency in finding a cure for this deadly virus. In this study, we reviewed the empiric options used in common practice for COVID-19, based on the literature available online, with an emphasis on human experiences with these treatments on severe acute respiratory syndrome-associated coronavirus (SARS-COV-1) and other viruses. Convalescent blood products are the most promising potential treatment for use in COVID-19. The use of chloroquine or hydroxychloroquine (HCQ), remdesivir, and tocilizumab are some of the other promising potential therapies; however, they are yet to be tested in randomized clinical trials (RCTs). The use of lopinavir-ritonavir did not prove beneficial in a large RCT. The use of corticosteroids should be avoided in COVID-19 pneumonia unless used for other indications, based on the suggestion of harm in patients with SARS-COV-1 and Middle Eastern Respiratory Syndrome (MERS) infection. The reviews of this paper are available via the supplemental material section. . Summary of the potential specific therapies of COVID-19. Mortality improvement with convalescent sera in Spanish flu, 2 H1N1 flu infection, 3 and no mortality benefit in Ebola infection. 4 Monoclonal antibodies mAb114 and REGN-EB3 were superior to remdesivir in reducing mortality in Ebola infection 5 In a case-series of five critically ill intubated, convalescent plasma transfusion was associated with clinical improvement in all five patients, a decrease in viral load, resolution of ARDS in four patients, extubation and discharge in three patients. 6 In another study of 10 severe COVID-19 patients, the transfusion led to the improvement in clinical symptoms in 3 days, and the disappearance of viremia along with radiological improvement in 7 days 7 Chloroquine phosphate/HCQ No optimal dosage defined. Chloroquine 500 mg oral daily (South Korea) 5-10 days, HCQ 600mg daily 8 5-10 days HCQ 400mg daily for 5 days 9 Diarrhea, QT prolongation Monitoring for QT prolongation and cardiovascular effects, especially if combined with azithromycin. A rare side effect of retinopathy in the long term and high dose use. HCQ is the less toxic form of chloroquine phosphate. Two clinical trials of HIV-1 at 800 mg/day HCQ dose decreased viral load and IL-6. 10, 11 Another clinical trial in HIV 1 patients with HCQ 400 mg/ day did not reduce viral load or change in immune activation 12 ribavirin and 1.5 g pulsed methylprednisolone, the patients were assigned to receive convalescent plasma or further pulsed steroids. Patients who received plasma had shorter hospital stay (adjusted discharge rate 77.8% versus 23%, p = 0.004) and lower mortality (0% versus 23.8%, p < 0.049). 35 In the H1N1 influenza pandemic, in a prospective cohort study, treatment with convalescent plasma reduced respiratory viral load and mortality (20% versus 54.8%). 36 The convalescent plasma was tested in the Ebola epidemic in a nonrandomized study of 84 patients with confirmed Ebola. It did not improve mortality (31% versus 38%, risk difference, −7% points; 95% CI, −18 to 4). 4 However, the authors later reported that the titers of anti-Ebola virus antibodies were low in many donations, and that the effectiveness of higher titer antibodies convalescent sera needed to be tested. 37 5 In a case-series of five critically ill intubated patients of COVID-19, who had a high viral load despite being previously treated with various antivirals and steroids, convalescent plasma was administered between 10 and 22 days of admission. The plasma transfusion was associated with clinical improvement, normalization of body temperature, and decrease in viral load in all the patients. Three out of five patients were extubated and discharged. 6 In another observational study of 10 severe COVID-19 patients, no serious side-effects were observed with the transfusion of convalescent plasma. The transfusion led to the improvement in clinical symptoms in 3 days and the disappearance of viremia along with radiological improvement in 7 days. 7 As the pandemic spreads, convalescent plasma will become an important potential therapy in the treatment of critically ill COVID-19 patients. 38 The development of monoclonal and polyclonal antibodies against COVID-19 is an area of active research. 38 In a non-peer reviewed pre-printed study from the Netherlands, 47D11 monoclonal antibody was reported to cross-neutralize COVID-19 and SARS-COV-1 by binding to its conserved epitope. 39 Convalescent blood products have a long track record of safety; however, they can increase the risk of antibody dependant enhancement of infection (ADE), a phenomenon that can make a person susceptible to infection with other viruses in the presence of antibodies. 40 Transfusion-related acute lung injury is also an important risk factor. 41 Thrombotic events are rare, but life-threatening complications associated with the transfusion of immunoglobulins. 42 Chloroquine phosphate and HCQ Chloroquine phosphate is known to inhibit COVID-19, 43 SARS COV-1, 44, 45 and influenza A and B virus in vitro, 46, 47 and HIV-1 in patients. 48, 49 Multiple mechanisms for the antiviral activity of chloroquine have been proposed. 50 Increased intracellular zinc levels with zinc ionophores that allow the entry of zinc into the cells have been shown to inhibit RNA-dependent RNA polymerase, an RNA synthesizing enzyme that is critical for the pathogenesis of positive-stranded RNA viruses. 51 The intracellular zinc levels are limited primarily by cell membrane structure, as demonstrated by the observation that the addition of zinc chloride only slightly increases intracellular zinc levels. 52 Chloroquine, however, is a zinc ionophore and significantly increases intracellular zinc levels. 52 In a study reported by the United States Centers for Disease Control and Prevention (CDC), chloroquine appears to interfere with the terminal glycosylation of the angiotensin-converting enzyme 2 (ACE 2), 45 in addition to the elevation in endosomal pH. ACE 2 is the receptor used by the SARS-COV virus to gain entry into cells. The authors concluded that the drug had a possible prophylactic and therapeutic use against SARS-COV-1 cell cultures. 45 HCQ is the less toxic derivative of chloroquine. In a recent in vitro study, it was found to be more potent than chloroquine against COVID-19. 53 In early clinical trials on HIV-1 patients, the use of HCQ monotherapy at 800 mg/day (equivalent to 500 mg/day chloroquine) resulted in decreased viral load. 10, 11 However, when it was used at 400 mg/day in another clinical trial, 12 it did not show any effect on viral load or immune activation. Attention should be paid to the dosing of HCQ, if used at all, for its antiviral effect. 54 Chloroquine failed to improve survival in mice and hamster models infected with Ebola virus. 55 In an unpublished news report from China, chloroquine demonstrated encouraging results in COVID-19 patients. 56 Based on these preliminary journals.sagepub.com/home/tar 5 results, a chloroquine sulfate 500 mg twice-daily dose was approved in China, 57 and chloroquine 500 mg once-daily dose was recommended in South Korea for critically ill or old patients. 58 60 Any conclusion from these studies is limited in the absence of a randomized control arm and a lack of clear clinical data. In a randomized control trial from Zhejiang by Chen et al., 30 patients were randomized to HCQ 400 mg daily for 5 days with conventional treatment to the control arm. No significant difference in nasopharyngeal viral carriage was noted in the two arms on day 7; however, the use of other antivirals may have confounded the results. 13 The study was not powered to detect any difference in clinical outcomes due to its small sample size. In another RCT from Wuhan, Chen et al. randomized HCQ 400 mg daily for 5 days to control arm in 62 COVID-19 patients. Shortened temperature recovery time, cough remission time, and increased absorption of pneumonia (80.6 versus 54.8%) were observed with HCQ treatment. 9 The data cannot be extrapolated to critically ill patients as only mildly severe COVID-19( SpO2 > 93%) patients were recruited in the study. 61 Large prospective clinical trial data in critically ill COVID-19 patients are awaited. Chloroquine and HCQ have a good safety profile overall. QT prolongation and cardiovascular effects are clinical concerns with high doses of chloroquine. QT prolongation should be monitored, especially if combining with azithromycin. Another rare side effect noted is retinopathy. However, retinal damage has been observed when chloroquine has been used for years in the treatment of autoimmune conditions. 62 Remdesivir is considered one of the promising antivirals in the armamentarium against COVID-19. 63 Remdisivir (developmental code GS-5734) is an experimental antiviral drug developed by Gilead Sciences. It is a monophosphoramidate prodrug of an adenosine analog. It has a broad spectrum of antiviral in vitro activity against other pathogenic RNA viruses, including Middle Eastern Respiratory Syndrome (MERS) and SARS-COV 1, bat COVs viruses. In the in vitro system of human airway epithelial cells, remdesivir inhibits MERS-COV and SARS-COV-1. The mouse model of SARS-COV1 demonstrated that the early administration of remdesivir decreased viral load, improved lung function, and the course of clinical disease. 64 As a nucleotide analog, remdesivir interferes with the activity of RNA polymerase and overcomes the intact exon proofreading ability, thus leading to the premature termination of the transcription. 65 It was effective in the treatment of Rhesus monkeys against EBOLA virus. 66 However, when subsequently tested in a clinical trial conducted during the Kivu Ebola epidemic, the monoclonal antibodies mAb114 and REGN-EB3 were superior to remdesivir in reducing mortality. 5 Remdesivir has been shown to inhibit COVID-19 potently in cell cultures. 43 In the compassionate use of remdesivir on 61 patients, clinical improvement was observed in 68% (36 out of 53) of the patients; however, any derivation of a conclusion is limited because of lack of comparator arm and lack of post-treatment data from 7 patients. Hepatic enzyme elevation was observed in 23% of the patients. 16 It is currently being tested for efficacy against COVID-19 in clinical trials in China. 67, 68 Favipiravir Favipiravir (Avigan) developed by Fujifilm Toyama Chemical has been effective against various RNA viruses, including influenza virus, arenaviruses, bunyaviruses, West Nile viruses, yellow fever viruses, and foot and mouth viruses. 69 It is effective against the H5N1 influenza virus in a mouse model; mice are poorly sensitive to oseltamivir. 70 Favipiravir is a nucleoside analog that requires intracellular phosphoribosylation to be converted into the active metabolite. The mechanism of action is inhibition of viral RNA-dependent RNA polymerase. 71 In the non-RCT against EBOLA virus disease, where a historic control arm was used to analyze the results, favipiravir was not effective as a stand-alone treatment in patients with very high viremia; however, it should be further studied in patients with relatively lower viral loads. Favipiravir was well tolerated in clinical trials. 15 Favipiravir is approved in Japan for the treatment of pandemic influenza infections. 72 Based on its broad-spectrum antiviral effect, favipiravir is thought to be a prime candidate for emerging RNA viruses. The bar for developing resistance against favipiravir is high. 72 In nonpeer-reviewed preprinted results from a clinical trial of 240 patients randomized for the use of favipiravir or arbidol on hospitalized SARS-COV-1 patients, favipiravir use was associated with the higher 7-day clinical recovery and more effective reduction in the incidence of fever and cough; however, no difference in oxygen requirement or non-invasive ventilation rate was noticed. 14 Favipiravir use was also associated with increased uric acid, psychiatric symptoms, gastrointestinal (GI) adverse effects, and increased liver function tests in 14% of the patients. 14 These results are reminiscent of favipiravir use in the Ebola epidemic, suggesting that favipiravir may not be as effective in severe cases compared with mild cases of COVID-19. Lopinavir is a protease inhibitor that, when combined with ritonavir, improves the mean trough plasma lopinavir concentration. It is approved for the treatment of HIV-infected patients. 73 Adverse effects of lopinavir-ritonavir include diarrhea, GI disturbances, headache, and skin rash. 74 Lopinavirritonavir and ribavirin showed an apparent favorable clinical response in 44 SARS-COV-1 patients when compared against 111 historic control ribavirin-treated patients. 17 In a double-blinded RCT on 199 patients infected with COVID-19 in China, lopinavir-ritonavir did not show any benefit beyond standard care (mortality19.2% versus 25.0%; difference, −5.8 percentage points; 95% CI, −17.3 to 5.7). 18 With these results from the clinical trial, lopinavir-ritonavir use should no longer be considered for the treatment of COVID-19, unless in the context of a clinical trial. Dysregulated immune response, including suppressed levels of interferons, have been observed with the infection of corona viruses. [75] [76] [77] [78] Human recombinant interferon inhibits SARS-COV-1 replication in vitro . [79] [80] [81] [82] In a non-human primate model in the common marmoset, the combination of interferon β1b and lopinavir/ritonavir was associated with better outcomes. 83 Ribavirin has been used in the past for the treatment of respiratory syncytial virus (RSV), Congo hemorrhagic fever, 84 and hepatitis C. 85 Ribavirin is a guanosine analog and interferes with polymerase inhibition, mRNA capping, and lethal mutagenesis. It has also been used in combination with interferon. The combination of interferon-α2b and ribavirin inhibited MERS-COV in vitro. 86 In a preliminary uncontrolled study on patients with SARS-COV-1, nine patients received interferon alfacon-1 with corticosteroids, and three patients were transferred to the ICU; however, none died. 87 In a retrospective cohort study of 44 critically ill MERS patients, 24 patients received interferon-alfa-2a and ribavirin; the therapy was associated with improved survival at 14 days but not at 28 days. 88 In another retrospective study of 32 MERS patients, interferon α2a or interferon β1a were used in combination with ribavirin. The mortality rate in patients who received interferon α2a was 85% compared with 64% in those who received interferon β1a. 22 These results did not suggest benefit with interferon and ribavirin since MERS-COV pneumonia mortality was thought to be around 67%. 89 In a multicenter observational study of 349 patients with critically ill MERS patients, 144 patients received interferon and ribavirin. They were not associated with any benefit in mortality or viral clearance. 19 The combination of interferon-alpha-2a and ribavirin in the clinical trial led to discontinuation of the medication in up to 27% of the patients receiving therapy for a year. 90 Interferon-alpha-2a and ribavirin have an unfavorable adverse effect profile, including significant depressive symptoms (21-58%), 20 anemia (34%), flu-like symptoms (22%), and GI symptoms (19.4%). 21 Based on mostly unfavorable experiences with MERS epidemics and high side-effect profile, the empiric combination should not be advocated in the absence of any clinical trial results on COVID-19. The idea of the use of steroids was coined in the treatment of acute respiratory distress in the meta-analysis on the effect of steroids in SARS-COV-1 by Stockman et al.; 25 studies were inconclusive, and only 4 studies were conclusive, all of which showed harm with the use of steroid. 23 Corticosteroids use in the first week were associated with delayed viral clearance in a randomized, double-blind placebo trial. 91 The other three studies reported psychosis, 25 diabetes, 26 and avascular necrosis. 27 Corticosteroid use was associated with delayed clearance of viral RNA in MERS-CoV infection. 28 In preliminary data from a retrospective cohort study from China in COVID-19, corticosteroids were used more often in patients who died (48%) than in patients who survived (23%), p < 0.001. 92 Based on this evidence, the World Health Organization (WHO) and other experts have recommended against the use of corticosteroid treatment against COVID-19 lung injury unless indicated for other indications. 29, 30 In the setting of cytokine storm, immunosuppression with steroids, if tocilizumab is not available, maybe considered. 93 Tocilizumab Tocilizumab is a humanized monoclonal antibody used in the treatment of rheumatoid arthritis, 94 juvenile idiopathic arthritis, 95 and cytokine release syndrome. 96 Tocilizumab blocks the interleukinsix (IL-6) receptor. IL-6 is a pro-inflammatory cytokine and can be released in response to viral infections. 97 In a study on 150 patients from Wuhan, China, IL-6, ferritin, and C reactive protein (CRP) were elevated in patients who died in comparison with those who survived. 98 These elevated laboratory markers suggest the possibility of hypercytokinemia in the setting of secondary hemophagocytic lymphohistiocytosis. 93 A viral infection is considered to be the most common trigger of secondary hemophagocytic lymphohistiocytosis. 99 Reports of the hemophagocytic syndrome have been noted in SARS-COV-1, 100 avian influenza, 101 and human influenza. 102, 103 Tocilizumab, approved for cytokine release syndrome, is being tested in a clinical trial from China in COVID-19 patients. 104 The use of H score for cytokine storm has been recommended to determine the critical timing of tocilizumab in severe COVID-19 patients. 93 In a retrospective observational pre-printed non-peer reviewed study from China, tocilizumab was used in 20 worsening COVID-19 patients; 75% of the patients had improvement in oxygen requirement, 90.5% of the patients had radiological improvement on computed tomography (CT) scan, CRP decreased significantly, and lymphocyte count initially decreased and then improved. 31 There was no randomized control arm in the study, a lack of data reported on the important inflammatory markers such as ferritin and IL-6, and only two patients were intubated prior to the use of tocilizumab in the study. These biases limit the derivation of any conclusion from the study. Elevated liver enzymes is a common adverse effect associated with tocilizumab. 105 The use of the Janus kinase (JAK) inhibitor baricitinib, which can inhibit clathrinmediated endocytosis, has also been considered as a potential option for hypercytokinemia. 106 Convalescent blood products are promising potential therapies for COVID-19. Other antivirals such as chloroquine or HCQ, remdesivir, and immune modulators such as tocilizumab are the other potential therapies for COVID-19 that are being tested in clinical trials. The use of antiretrovirals, such as lopinavir/ritonavir, did not provide any benefit in a RCT. Steroids appear to be harmful based on human experiences with SARS-COV-1 and MERS infection. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis Evaluation of convalescent plasma for Ebola virus disease in Guinea A randomized, controlled trial of Ebola virus disease therapeutics Treatment of 5 critically ill patients with COVID-19 with convalescent plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1 Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1 Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 Favipiravir versus Arbidol for COVID-19: a randomized clinical trial Experimental treatment with Favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-ofconcept trial in Guinea Compassionate use of remdesivir for patients with severe Covid-19 Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome Neuropsychiatric adverse effects of interferon-α Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study SARS: systematic review of treatment effects Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study Glucocorticoidinduced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected Effective treatment of severe COVID-19 patients with tocilizumab Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets Convalescent plasma: new evidence for an old therapeutic tool? Use of convalescent plasma therapy in SARS patients in Hong Kong Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection Efficacy of convalescent plasma in relation to dose of Ebola virus antibodies Convalescent plasma as a potential therapy for COVID-19 A human monoclonal antibody blocking SARS-CoV-2 infection Molecular mechanism for antibody-dependent enhancement of coronavirus entry Transfusionrelated acute lung injury in the critically ill: prospective nested case-control study Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro In vitro inhibition of severe acute respiratory syndrome journals.sagepub.com/home/tar coronavirus by chloroquine Chloroquine is a potent inhibitor of SARS coronavirus infection and spread New insights into the antiviral effects of chloroquine Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy Effects of chloroquine on viral infections: an old drug against today's diseases New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture Chloroquine is a zinc ionophore Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS Lack of protection against ebola virus from chloroquine in mice and hamsters Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia Physicians work out treatment guidelines for coronavirus Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base Chloroquine retinopathy: is there a safe daily dose? Compounds with therapeutic potential against novel respiratory 2019 coronavirus Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys Severe 2019-nCoV remdesivir RCT -Full Text View -ClinicalTrials.gov, journals.sagepub.com/home/tar 11 Mild/moderate 2019-nCoV remdesivir RCT -Full Text View -ClinicalTrials T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections Efficacy of orally administered T-705 on lethal Avian influenza A (H5N1) virus infections in mice The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase Favipiravir as a potential countermeasure against neglected and emerging RNA viruses Lopinavir-Ritonavir versus Nelfinavir for the initial treatment of HIV infection A review of treatment modalities for Middle East respiratory syndrome Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice Interferon-γ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells Treatment of SARS with human interferons Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin Interferon Alfacon-1 plus corticosteroids in severe acute respiratory syndromea preliminary study Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of journals.sagepub.com/home/tar chronic infection with hepatitis C virus Effects of early corticosteroid treatment on plasma SARSassociated Coronavirus RNA concentrations in adult patients Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. Epub ahead of print 11 COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. Epub ahead of print 16 Tocilizumab for rheumatoid arthritis: a Cochrane systematic review Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. Epub ahead of print 3 Adult haemophagocytic syndrome The comparative pathology of severe acute respiratory syndrome and avian influenza A subtype H5N1-a review Pathology of fatal human infection associated with avian influenza A H5N1 virus Influenza A and the virus associated haemophagocytic syndrome: cluster of three cases in children with acute leukaemia Hemophagocytic lymphohistiocytosis complicating influenza A infection randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia Clinical safety of tocilizumab in rheumatoid arthritis COVID-19: combining antiviral and anti-inflammatory treatments We would like to acknowledge James Sullivan, who helped in the review of the manuscript.